CreatorsPublishersAdvertisers
View more in
Cancer

Durvalumab and Chemotherapy, Plus or Minus Tremelimumab Yields Survival Benefit in Frontline Treatment of Advanced NSCLC

cancernetwork.com
 2021-09-09

Cover picture for the articleThe phase 3 POSEIDON trial indicated that patients with metastatic non–small cell lung cancer who were treated with first-line durvalumab and chemotherapy with or without tremelimumab experienced a statistically significant survival benefit. A statistically significant improvement in progression-free survival (PFS) was obtained utilizing a first-line combination of durvalumab (Imfinzi)...

www.cancernetwork.com

Comments / 0

Comments / 0